Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab

Copanlisib dose selection was established under the maximum tolerated dose paradigm, and no dedicated dose‐finding studies have investigated copanlisib dose selection when used in combination with rituximab. In CHRONOS‐3, copanlisib plus rituximab demonstrated significantly improved progression‐free...

Descripción completa

Detalles Bibliográficos
Autores principales: Morcos, Peter N., Moss, Jonathan, Austin, Rupert, Hiemeyer, Florian, Zinzani, Pier Luigi, Beckert, Vita, Mongay Soler, Lidia, Childs, Barrett H., Garmann, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681405/
https://www.ncbi.nlm.nih.gov/pubmed/37389853
http://dx.doi.org/10.1002/psp4.13000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681405/
https://www.ncbi.nlm.nih.gov/pubmed/37389853
http://dx.doi.org/10.1002/psp4.13000

Ejemplares similares